A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)
- 28/10/2018
- 3377
- Comments Off on MK-3475-091/KEYNOTE-091 (PEARLS)